SLCO1B1 gene single nucleotide polymorphism is a drug response marker for pancreatic cancer patients treated with gemcitabine

被引：0
|
作者：
Ueno, H. [1 ]
Ioka, T. [2 ]
Ohkawa, S. [3 ]
Ikeda, M. [4 ]
Shimamura, T. [5 ]
Tsuji, A. [6 ]
Tsuchiya, Y. [7 ]
Okusaka, T. [1 ]
Yoshida, T. [8 ]
Sato, Y. [9 ]
机构：
[1] Natl Canc Ctr, Hepatobiliary & Pancreat Oncol Div, Tokyo, Japan
[2] Osaka Med Ctr Canc & Cardiovasc Dis, Div Hepatobiliary & Pancreat Oncol, Osaka, Japan
[3] Kanagawa Canc Ctr, Div Gastroenterol, Kawasaki, Kanagawa, Japan
[4] Natl Canc Ctr Hosp East, Div Hepatobiliary & Pancreat Oncol, Chiba, Japan
[5] Saitama Canc Ctr, Dept Gastroenterol, Saitama, Japan
[6] Kochi Hlth Sci Ctr, Dept Clin Oncol, Kochi, Japan
[7] Niigata Canc Ctr Hosp, Div Surg, Niigata, Japan
[8] Natl Canc Ctr, Div Genet, Tokyo, Japan
[9] Chiba Univ Hosp, Clin Res Ctr, Chiba, Japan
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2582
引用
收藏
页码：S613 / S613
页数：1
相关论文
共 50 条
  • [21] The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy
    Romaine, S. P. R.
    Bailey, K. M.
    Hall, A. S.
    Balmforth, A. J.
    PHARMACOGENOMICS JOURNAL, 2010, 10 (01): : 1 - 11
  • [22] No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone
    Kalliokoski, Annikka
    Neuvonen, Mikko
    Neuvonen, Pertti J.
    Niemi, Mikko
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 (01) : 78 - 86
  • [23] No significant effect of the SLCO1B1 polymorphism on the pharmacokinetics of ursodeoxycholic acid
    Xiang, Xiaoqiang
    Vakkilainen, Juha
    Backman, Janne T.
    Neuvonen, Pertti J.
    Niemi, Mikko
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 67 (11) : 1159 - 1167
  • [24] No significant effect of the SLCO1B1 polymorphism on the pharmacokinetics of ursodeoxycholic acid
    Xiaoqiang Xiang
    Juha Vakkilainen
    Janne T. Backman
    Pertti J. Neuvonen
    Mikko Niemi
    European Journal of Clinical Pharmacology, 2011, 67 : 1159 - 1167
  • [25] SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin
    Niemi, Mikko
    Pasanen, Marja K.
    Neuvonen, Pertti J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (04) : 356 - 366
  • [26] Influence of SLCO1B1 polymorphism on maintenance therapy for childhood leukemia
    Suzuki, Ryoko
    Fukushima, Hiroko
    Noguchi, Emiko
    Tsuchida, Masahiro
    Kiyokawa, Nobutaka
    Koike, Kazutoshi
    Ma, Enbo
    Takahashi, Hideto
    Kobayashi, Chie
    Nakajima-Yamaguchi, Ryoko
    Sakai, Aiko
    Saito, Makoto
    Iwabuchi, Atsushi
    Kato, Keisuke
    Nakao, Tomohei
    Yoshimi, Ai
    Sumazaki, Ryo
    Fukushima, Takashi
    PEDIATRICS INTERNATIONAL, 2015, 57 (04) : 572 - 577
  • [27] Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin
    Pasanen, M. K.
    Fredrikson, H.
    Neuvonen, P. J.
    Niemi, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 82 (06) : 726 - 733
  • [28] SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid
    Tornio, Aleksi
    Vakkilainen, Juha
    Neuvonen, Mikko
    Backman, Janne T.
    Neuvonen, Pertti J.
    Niemi, Mikko
    PHARMACOGENETICS AND GENOMICS, 2015, 25 (08): : 382 - 387
  • [29] SLCO1B1*5 polymorphism and the interaction between rifampicin and atorvastatin
    不详
    PHARMACOGENOMICS, 2010, 11 (03) : 294 - 294
  • [30] EFFECTS OF SLCO1B1 GENETIC POLYMORPHISM ON THE PHARMACOKINETICS OF PITAVASTATIN IN KOREANS
    Choi, C., I
    Bae, J. W.
    Lee, H., I
    Kim, M. J.
    Jang, C. G.
    Lee, S. Y.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 79 - 79
12345